Exclusion criteria | |
---|---|
Consent/communication | Inability to speak or read English |
Mental health | |
Lifetime | History of psychotic disorder |
Current | Any unstable medical or neurologic condition, judged at the discretion of the clinician |
Imminent risk of suicide as determined by the MADRS/clinical interview | |
Substance abuse or dependence in previous 3 months | |
Stage 3 treatment-resistant depression or higher as determined by Thase and Rush Staging criteria [21] | |
Receiving neuromodulation treatment | |
Undergoing planned changes to psychotropic medication | |
Drug contraindications | Significant renal or hepatic impairment |
Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening | |
Glaucoma | |
Female participants who are pregnant, lactating, or planning pregnancy during the course of the trial | |
Contraindication to the use of scopolamine or glycopyrrolate according to manufacturer guidelines | |
Regular use of any medication deemed to be contraindicated as judged by the attending study physicians | |
Other safety criteria | Inability to fast for 2 hours prior to each administration of trial drug |
Any other condition judged by the study clinicians as likely to impact on the ability of the participant to complete the trial | |
Are currently attending a New Zealand specialist mental health or addiction service |